Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solnerstotug, an antibody targeting VSIR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sutacimig, an antibody targeting F7a × TREML1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Spevatamig, an antibody targeting IAP × Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pamlectabart, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Peluntamig, an antibody targeting IAP × DLL3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Solabafusp, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imneskibart, an antibody targeting IL2RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Greziprubart, an antibody targeting C5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eclutatug, an antibody targeting CLDN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ciletatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Brivestobart, an antibody targeting LAG-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ulocuplumab, an antibody targeting CXCR4.